Novo Nordisk cardio push picks up Phase 2-ready Prothena drug in $100M deal
Novo Nordisk is paying $100 million up front to acquire an experimental Prothena drug being developed to treat heart problems stemming from a misfolded protein. The deal is part of a broader strategy to expand into drugs for cardiovascular disease.